Pfizer Provided Grants to Vaccination Lobbying Groups
The pharmaceutical company awarded $500,000 to two nonprofits that later supported a Massachusetts vaccine bill.
Updated on Sept. 22, 2026 in Philanthropy
Live Poll
Should pharmaceutical companies be allowed to fund nonprofit organizations that advocate for public health policy?
In 2024, Pfizer disclosed $500,000 in grant funding given to two nonprofit organizations. These groups subsequently signed a coalition letter supporting House Bill 2554, which seeks to eliminate religious exemptions for school vaccinations in Massachusetts.
Why it matters
The funding highlights the intersection between corporate pharmaceutical philanthropy and public health advocacy. Supporters of the bill believe limiting exemptions bolsters community immunity, while opponents emphasize the importance of religious freedom and parental choice.
Pfizer issued $500,000 in grants during 2024 to two nonprofit organizations that joined a coalition letter on June 1, 2026. The funds were disclosed as part of the company's mandatory corporate transparency programme.
The players
Pfizer
Pfizer is a multinational pharmaceutical and biotechnology corporation that develops and manufactures medicines and vaccines.
March of Dimes
March of Dimes is a nonprofit organization that works to improve the health of mothers and babies through research, advocacy, and education.
ASMP
ASMP is a nonprofit organization focused on professional standards and advocacy within the medical community.
The details
The grant recipients, ASMP and March of Dimes, signed a letter addressed to the Massachusetts House Committee on Ways and Means on June 1, 2026, advocating for the passage of House Bill 2554. This legislation aims to remove religious exemptions for school vaccinations, though medical exemptions would remain under current state law.
Timeline
Pfizer provided the grant funding during 2024.
The House Committee on Public Health reported the bill favorably in July 2025.
House Bill 2554 was referred to the House Committee on Ways and Means on April 15, 2026.
The coalition letter in support of the bill was signed on June 1, 2026.
Market Landscape
The funding of advocacy groups by pharmaceutical companies follows a broader trend of industry-backed lobbying for state-level health mandates. This strategy positions major manufacturers as key players in shaping public health policy, often competing against grassroots parental advocacy groups.
The potential passage of House Bill 2554 would directly impact parents in Massachusetts by removing the option for religious exemptions for school-aged children. Residents may see changes to public school enrollment requirements and health compliance standards if the bill becomes law.
The takeaway
Public policy decisions regarding health often involve complex financial support from stakeholders with a vested interest in medical coverage. Residents should stay informed about legislative activity to understand how advocacy funding may influence state health regulations.
Further reading
For more information on the influence of private funding in regional initiatives, visit Philanthropy.
Source note: This article includes information reported by National Daily NG.
Live Poll
Should pharmaceutical companies be allowed to fund nonprofit organizations that advocate for public health policy?
